GMCI plus Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Patients (LuTK02)

GMCI plus Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Patients (LuTK02)

Brief description of study

This trial is to evaluate the safety and efficacy of adding GMCI to standard of care in patients with stage III/IV NSCLC that are not responding to a first line immune checkpoint inhibitor (ICI).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Non Small Lung Cancer,Non Small Lung Cancer
  • Age: Between 18 Years - 99 Years
  • Gender: All

Male or Female 18 years of age or older Non Small Lung cancer

Updated on 09 Mar 2024. Study ID: 844087

Find a site

What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center